About

The Accelerating Medicines Partnership (AMP®) Schizophrenia (SCZ) program aims to clarify the disease pathways and long-term outcomes of people who are at risk for schizophrenia and to identify new and better targets for early treatment.

People

The following individuals are the Principal Investigators for The Accelerating Medicines Partnership (AMP®) SCZ program. Click on their bios to learn more.

Barnaby Nelson, Ph.D. Picture

Barnaby Nelson, Ph.D.

Center for Youth Mental Health at the University of Melbourne; Orygen

Bio

Martha E. Shenton, Ph.D. Picture

Martha E. Shenton, Ph.D.

Harvard Medical School; Psychiatry Neuroimaging Laboratory at Brigham and Women's Hospital

Bio

Scott Woods, M.D. Picture

Scott Woods, M.D.

Yale University

Bio

Carrie Bearden, Ph.D. Picture

Carrie Bearden, Ph.D.

University of California, Los Angeles

Bio

Rene Kahn, M.D., Ph.D. Picture

Rene Kahn, M.D., Ph.D.

Icahn School of Medicine at Mount Sinai

Bio

John Kane, M.D. Picture

John Kane, M.D.

Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Bio

Patrick McGorry, M.D., Ph.D. Picture

Patrick McGorry, M.D., Ph.D.

Center for Youth Mental Health at the University of Melbourne; Orygen

Bio

Last Reviewed on May 2, 2022